Latest Balance Sheet News

Solvar Limited reported a notable 84.4% jump in net profit for FY25 even as revenue declined 6.1%, alongside a healthy dividend increase.

SPC Global Holdings Ltd has reported FY25 proforma results exceeding guidance with a normalised EBITDA of $30.3 million, setting the stage for ambitious growth and international expansion in FY26.

Titomic Limited reported a 22.5% increase in revenue to $9.43 million for FY2025 but saw losses soar by over 67%, highlighting ongoing financial challenges despite growth.

Clever Culture Systems Ltd has reported a remarkable 288% jump in revenue to $6.63 million for the year ended June 2025, turning around from a loss to a net profit of $1.68 million, buoyed by strong product sales and government support.

WT Financial Group Limited reported a robust FY2025 with a 17.3% rise in gross revenue and a 20.5% increase in net profit after tax, underpinned by its dominant B2B financial adviser network. The company also announced a fully franked final dividend and a strategic joint venture poised to fuel future growth.

De.mem Limited has reported a record half-year performance for 2025, with revenue up 20% and its first positive adjusted EBITDA, driven by strong recurring revenues and strategic acquisitions.

Resimac Group Ltd reported a stable FY25 net profit after tax of $34.6 million and declared a fully franked final dividend of 3.5 cents per share, maintaining its steady financial footing amid modest revenue growth.

Anagenics Limited has revealed a significant 52.6% decline in revenue alongside an 83.5% increase in net loss for the financial year ended June 2025, marking a challenging period for the biotech company.

Farm Pride Foods Ltd has reported a remarkable 384% increase in net profit for the financial year ending June 2025, despite revenues remaining virtually unchanged. The company’s financial health shows signs of strengthening, though no dividends were declared.

Vitasora Health reported a sharp rise in losses and operating cash outflows for FY2025, despite achieving significant cost savings from its Orb Health acquisition. The company faces a material uncertainty over its ability to continue as a going concern.

Clinuvel Pharmaceuticals has reported a robust financial year ending June 2025, marked by solid revenue growth and sustained profitability, while advancing its clinical pipeline and maintaining a strong balance sheet.

Clinuvel Pharmaceuticals has reported its ninth consecutive year of revenue and profit growth, driven by strong sales of SCENESSE® and strategic investment in vitiligo clinical trials. The company also declared its eighth consecutive dividend, underscoring financial resilience.